Drug profile · INN
deucravacitinib
SOTYKTU
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
deucravacitinib (SOTYKTU) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN deucravacitinib
Brand SOTYKTU
Route ORAL
Formulation TABLET
ATC code L04AF07
Originator Bristol-Myers Squibb Australia Pty Ltd
Frequently asked questions
What is deucravacitinib?
deucravacitinib (SOTYKTU) is an FDA-listed pharmaceutical active ingredient. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for deucravacitinib?
SOTYKTU is a marketed brand name for deucravacitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of deucravacitinib?
deucravacitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.